Vaxcyte, Inc. cotiza a 71.38 USD y tiene una capitalización bursátil de $10.6B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-1.97 | $-2.30 | $-1.80 |
| Estimado | $-2.14 | $-2.10 | $-1.77 | $-1.50 |
| Sorpresa | — | +6.2% | -29.9% | -20.0% |
| Métrica | PCVX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -28.6% | -40.4% | +11.8% |
| ROA | -25.5% | -32.0% | +6.5% |
| Current Ratio | 7.91 | 2.84 | +5.07 |
| Debt / Equity | — | 0.28 | — |